A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Merck Sharp & Dohme LLC
AstraZeneca
Qilu Pharmaceutical Co., Ltd.
Genmab
AstraZeneca
AstraZeneca
Merck Sharp & Dohme LLC
Eli Lilly and Company
AstraZeneca
GlaxoSmithKline
Blueprint Medicines Corporation
Avenzo Therapeutics, Inc.
Eli Lilly and Company
Merck Sharp & Dohme LLC
Bio-Thera Solutions
GlaxoSmithKline
AstraZeneca
Merck Sharp & Dohme LLC
Inspirna, Inc.
Huabo Biopharm Co., Ltd.
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
NETRIS Pharma
Advenchen Laboratories, LLC
Ability Pharmaceuticals SL
Sanofi